EUVIMEDEUVIMED entdecken
Klinische Studie (Phase I)

A phase I clinical trial of sonodynamic therapy combined with radiotherapy for brainstem gliomas

Linkuan Huangfu iD, Boya Zha, Peihong Li, Long Wang, Xiaohao Liu, Haiyang Cui, Yuxin Li, Jingjing Wu, Shuling Shi, Yuchuan Yang, Xiaocong Sun, Shibo Gao und 3 weitere

International Journal of Cancer · 2025

DOI: 10.1002/ijc.35218 ↗

Kurz gefasst

Klinische Studie (Phase I) in der Zeitschrift International Journal of Cancer, 2025. Verfasst von Linkuan Huangfu und 14 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiotherapy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, People's Republic of China. Hauptthemen laut MEDLINE: Glioma, Brain Stem Neoplasms. Die Arbeit wurde bisher 22-mal zitiert (Crossref) und nennt 45 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Brainstem gliomas (BSGs) are a class of clinically refractory malignant tumors for which there is no uniform and effective treatment protocol. Ultrasound and radiation can activate hematoporphyrin and produce sonodynamic and radiodynamic effects to kill cancer cells. Therefore, we conducted the first phase I clinical trial of sonodynamic therapy (SDT) combined with radiotherapy (RT) for the treatment of BSGs to verify its safety and efficacy. We conducted a study of SDT combined with RT in 11 patients with BSGs who received SDT and RT after hematoporphyrin administration. Magnetic resonance imaging was performed during this period to assess the tumor, and adverse events were recorded. All adverse events recorded were grade 1–2; no grade 3 or more serious adverse events were observed. Treatment was well tolerated, and no dose‐limiting toxicities were observed. There were no treatment‐related deaths during the course of treatment. 8 of 11 patients (72.7%) maintained stable disease, 2 (18.2%) achieved partial response, and the tumors were still shrinking as of the last follow‐up date. The median progression‐free survival (PFS) for patients was 9.2 (95% confidence interval [CI] 6.2–12.2) months, and the median overall survival (OS) was 11.7 (95% CI 9.6–13.8) months. Therefore, SDT combined with RT has a favorable safety and feasibility and shows a preliminary high therapeutic potential.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GliomaBrain Stem NeoplasmsHumansMaleFemaleAdultMiddle AgedCombined Modality TherapyUltrasonic TherapyHematoporphyrinsYoung AdultMagnetic Resonance ImagingAgedProgression-Free SurvivalTreatment Outcome

Stichwörter der Autor:innen

brainstem gliomahematoporphyrinradiodynamicsradiotherapysonodynamic therapy

Substanzen

Hematoporphyrins

Autor:innen und Institutionen

  • Department of Radiotherapy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, People's Republic of China.
  • Department of Hyperthermia and Photodynamic Therapy, the First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan Province, People's Republic of China.

ORCID-Profile: Linkuan Huangfu, Daoke Yang, Yingjuan Zheng

Zitieren

APA

Huangfu, L., Zha, B., Li, P., Wang, L., Liu, X., Cui, H., Li, Y., Wu, J., Shi, S., Yang, Y., Sun, X., Gao, S., Li, H., Yang, D., & Zheng, Y. (2025). A phase I clinical trial of sonodynamic therapy combined with radiotherapy for brainstem gliomas. International Journal of Cancer. https://doi.org/10.1002/ijc.35218

Vancouver

Huangfu L, Zha B, Li P, Wang L, Liu X, Cui H, et al. A phase I clinical trial of sonodynamic therapy combined with radiotherapy for brainstem gliomas. International Journal of Cancer. 2025. doi:10.1002/ijc.35218

BibTeX
@article{Huangfu2025,
  author = {Huangfu, Linkuan and Zha, Boya and Li, Peihong and Wang, Long and Liu, Xiaohao and Cui, Haiyang and Li, Yuxin and Wu, Jingjing and Shi, Shuling and Yang, Yuchuan and Sun, Xiaocong and Gao, Shibo and Li, Huizhen and Yang, Daoke and Zheng, Yingjuan},
  title = {A phase I clinical trial of sonodynamic therapy combined with radiotherapy for brainstem gliomas},
  journal = {International Journal of Cancer},
  year = {2025},
  doi = {10.1002/ijc.35218}
}
Kostenlos starten →